2135696-72-7
Kinase inhibitor-1
CAS: 2135696-72-7
Molecular Formula: C19H18BrClN6O
2135696-72-7 - Names and Identifiers
| Name | Kinase inhibitor-1 |
| Synonyms | Tarlox-TKI Kinase inhibitor-1 2-Butenamide, N-[4-[(3-bromo-4-chlorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)-, (2E)- |
| CAS | 2135696-72-7 |
2135696-72-7 - Physico-chemical Properties
| Molecular Formula | C19H18BrClN6O |
| Molar Mass | 461.74 |
| Density | 1.552±0.06 g/cm3(Predicted) |
| Boling Point | 647.4±55.0 °C(Predicted) |
| pKa | 9.68±0.43(Predicted) |
| Storage Condition | 2-8℃ |
| Use | Kinase inhibitor-1 (Compound 5) is a Kinase inhibitor. |
| In vitro study | Epidermal Growth Factor Receptor (EGFR, HER1) is an attractive therapeutic target for many cancer types. Tarlox-TKI is a dose-potent EGFR inhibitor. |
2135696-72-7 - Introduction
Kinase inhibitor-1 (Kinase inhibitor-1) is a compound that inhibits the enzymatic activity of protein kinases. It can act on various protein kinases to regulate cell signaling pathways. Kinase inhibitor-1 can be used in cancer therapy because many cancers are associated with aberrantly activated protein kinases. It may also be used in the treatment of inflammation, autoimmune diseases and other diseases.
The preparation of Kinase inhibitor-1 usually adopts organic synthesis method. A common method is to build the molecular structure of two or more chemical substances by reacting them. The specific synthetic route varies depending on the chemical structure.
Regarding safety information, Kinase inhibitor-1 is an active compound and requires careful handling when used. It may have toxic effects on the human body, and has certain side effects and potential adverse reactions. Therefore, adequate toxicity and safety assessments are required prior to use, and proper practice and personal protective measures are followed. In addition, it is also necessary to properly store and discard the compound to avoid pollution to the environment. For specific safety information, please refer to the compound's safety data sheet (SDS) and relevant research literature.
The preparation of Kinase inhibitor-1 usually adopts organic synthesis method. A common method is to build the molecular structure of two or more chemical substances by reacting them. The specific synthetic route varies depending on the chemical structure.
Regarding safety information, Kinase inhibitor-1 is an active compound and requires careful handling when used. It may have toxic effects on the human body, and has certain side effects and potential adverse reactions. Therefore, adequate toxicity and safety assessments are required prior to use, and proper practice and personal protective measures are followed. In addition, it is also necessary to properly store and discard the compound to avoid pollution to the environment. For specific safety information, please refer to the compound's safety data sheet (SDS) and relevant research literature.
Last Update：2024-04-09 20:52:54
